JP Morgan Chase
AST

JP Morgan Chase’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

JP Morgan Chase’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-49
Closed – – 6182
2018
Q3 		$0 Buy
+49
New +$76 ﹤0.01% 6012
2018
Q2 		– Sell
-5,956
Closed -$9K – 5888
2018
Q1 		$9K Sell
5,956
-425
-7% -$888 ﹤0.01% 5192
2017
Q4 		$14K Buy
+6,381
New +$16.1K ﹤0.01% 5223
2017
Q1 		– Sell
-11,415
Closed -$53K – 5443
2016
Q4 		$53K Buy
+11,415
New +$47.1K ﹤0.01% 4536
2016
Q2 		– Sell
-742
Closed -$3K – 5245
2016
Q1 		$3K Buy
+742
New +$2.87K ﹤0.01% 4497

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase's AST Position: Q4 2018 in Review

JP Morgan Chase sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 49 shares.

JP Morgan Chase first reported a position in AST in Q1 2016 and held it in 5 quarters. The position peaked at $53K in Q4 2016. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.

  • JP Morgan Chase reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
  • JP Morgan Chase sold 49 Asterias Biotherapeutics Inc. Series A shares in Q4 2018.
  • JP Morgan Chase first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2016 and held it in 5 quarters.
  • JP Morgan Chase's Asterias Biotherapeutics Inc. Series A position peaked at $53K in Q4 2016.
  • 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.

Based on JP Morgan Chase's 13F filing for Q4 2018, filed 11 Feb 2019.